Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRESILLION cobalt chromium stent · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | The PRESILLION TM Coronary Stent is an L-605 cobalt chromium (CoCr) stent. |
| Name | Type | Description |
|---|---|---|
| PRESILLION cobalt chromium stent | DEVICE | PTCA with bare-metal stent |
Inclusion Criteria: * The patient must be \>= 18 years of age. * Patient is eligible for percutaneous coronary intervention (PCI). * Acceptable candidate for coronary artery bypass surgery (CABG). * Female patients of childbearing potential must have a negative pregnancy test within 7 days prior to...
The PRESILLION cobalt chromium stent is used for treating Coronary Artery Disease. It is a coronary stent designed to be implanted in de novo coronary lesions. The device is currently in clinical development and is not yet approved for commercial use.
The PRESILLION cobalt chromium stent is developed by Cardinal Health, Inc., which trades under the ticker CAH. The company is conducting clinical trials to evaluate the safety and effectiveness of this coronary stent for patients with Coronary Artery Disease.
The PRESILLION cobalt chromium stent is in Phase 3 clinical development. It is an investigational device, meaning it has not yet received regulatory approval. One Phase 3 trial has been completed, and the device is not currently in active clinical trials.
The PRESILLION cobalt chromium stent has been studied in one completed Phase 3 trial, NCT00722579, titled 'A Study of the Presillion Stent in de Novo Coronary Lesions.' This trial enrolled 101 participants with Coronary Artery Disease and was conducted in Belgium.
Yes, the PRESILLION cobalt chromium stent is the same as the Presillion stent. The clinical trial NCT00722579 refers to it as the 'Presillion Stent,' and the full product name includes 'cobalt chromium' to describe the stent material. Both names refer to the same investigational device.